These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 18474513

  • 1. BSAC standardized disc susceptibility testing method (version 7).
    Andrews JM, BSAC Working Party on Susceptibility Testing.
    J Antimicrob Chemother; 2008 Aug; 62(2):256-78. PubMed ID: 18474513
    [Abstract] [Full Text] [Related]

  • 2. BSAC standardized disc susceptibility testing method (version 8).
    Andrews JM, BSAC Working Party on Susceptibility Testing.
    J Antimicrob Chemother; 2009 Sep; 64(3):454-89. PubMed ID: 19587067
    [Abstract] [Full Text] [Related]

  • 3. BSAC standardized disc susceptibility testing method (version 10).
    Andrews JM, Howe RA, BSAC Working Party on Susceptibility Testing.
    J Antimicrob Chemother; 2011 Dec; 66(12):2726-57. PubMed ID: 21921076
    [Abstract] [Full Text] [Related]

  • 4. Colistin susceptibility testing by Etest and disk diffusion methods.
    Galani I, Kontopidou F, Souli M, Rekatsina PD, Koratzanis E, Deliolanis J, Giamarellou H.
    Int J Antimicrob Agents; 2008 May; 31(5):434-9. PubMed ID: 18328674
    [Abstract] [Full Text] [Related]

  • 5. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
    Hope R, Parsons T, Mushtaq S, James D, Livermore DM.
    J Antimicrob Chemother; 2007 Oct; 60(4):770-4. PubMed ID: 17704517
    [Abstract] [Full Text] [Related]

  • 6. Validation of EUCAST zone diameter breakpoints against reference broth microdilution.
    Bengtsson S, Bjelkenbrant C, Kahlmeter G.
    Clin Microbiol Infect; 2014 Jun; 20(6):O353-60. PubMed ID: 24118469
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, Mulvey MR, Hoban DJ, Canadian Antimicrobial Resistance Alliance.
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
    [Abstract] [Full Text] [Related]

  • 8. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN.
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [Abstract] [Full Text] [Related]

  • 9. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria.
    Andrews JM, Ashby JP, Jevons GM, Wise R.
    J Antimicrob Chemother; 1999 Dec; 44(6):819-22. PubMed ID: 10590284
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
    Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS.
    J Antimicrob Chemother; 2005 Dec; 56(6):1047-52. PubMed ID: 16239290
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.
    Hope R, Mushtaq S, James D, Pllana T, Warner M, Livermore DM, Tigecycline Susceptibility Testing Group.
    J Antimicrob Chemother; 2010 Dec; 65(12):2602-9. PubMed ID: 20930043
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance.
    Ringertz S, Olsson-Liljequist B, Kahlmeter G, Kronvall G.
    Scand J Infect Dis Suppl; 1997 Dec; 105():8-12. PubMed ID: 9435026
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
    DeRyke CA, Kuti JL, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. How does susceptibility prevalence impact on the performance of disk diffusion susceptibility testing?
    Lamy B, Carret G, Flandrois JP, Delignette-Muller ML.
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):131-9. PubMed ID: 15183863
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.
    Hombach M, Bloemberg GV, Böttger EC.
    J Antimicrob Chemother; 2012 Mar; 67(3):622-32. PubMed ID: 22167240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.